The Jubilant Ingrevia Limited (NSE:JUBLINGREA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Jubilant Ingrevia Limited (NSE:JUBLINGREA) last week reported its latest first-quarter results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. It was a workmanlike result, with revenues of ₹13b coming in 3.0% ahead of expectations, and statutory earnings per share of ₹6.68, in line with analyst appraisals. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Following the latest results, Jubilant Ingrevia's seven analysts are now forecasting revenues of ₹53.2b in 2027. This would be a decent 14% improvement in revenue compared to the last 12 months. Per-share earnings are expected to shoot up 30% to ₹25.45. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹52.3b and earnings per share (EPS) of ₹24.48 in 2027. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
See our latest analysis for Jubilant Ingrevia
There's been no major changes to the consensus price target of ₹967, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Jubilant Ingrevia analyst has a price target of ₹1,200 per share, while the most pessimistic values it at ₹711. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Jubilant Ingrevia's rate of growth is expected to accelerate meaningfully, with the forecast 20% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 0.3% p.a. over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Jubilant Ingrevia is expected to grow much faster than its industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Jubilant Ingrevia following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at ₹967, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Jubilant Ingrevia analysts - going out to 2029, and you can see them free on our platform here.
You can also see whether Jubilant Ingrevia is carrying too much debt, and whether its balance sheet is healthy, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.